Inaug.-diss.--Basel. / Lebenslauf.

Thesis (M.S.)--University of Wisconsin--Madison, 1969. / eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references.

Thesis (Ph.D.)--University of North Carolina at Greensboro, 2007. / Title from PDF t.p. (viewed Oct. 22, 2007). Directed by Nancy Myers; submitted to the Dept. of English. Includes bibliographical references (p. 209-228).

The SA Code of Practice for the Marketing of Medicines was formulated in an attempt to reduce the cost of medicines, thus ruling out certain marketing practices. This research report investigated what the perceived impact of the Code may be on customer equity in an already volatile industry. Quantitative, cross-sectional research was undertaken. A pre-tested, selfadministered, e-mail survey based on the regulations of the Code was distributed to key account retail pharmacies of a particular pharmaceutical company in South Africa. Four hypotheses were statistically tested at significance levels of 0,1 %, 1 % and 5 %. Inferences were then drawn based on the quantitative analyses. The results show that the market is in favour of the “Code-not-condoned” value, brand and relationship equity marketing practices; thus the Code’s impact may be perceived as negative. Pharmaceutical firms should be careful in selecting “Code-condoned” marketing practices, as these may not contribute to customer equity. This aspect adds to the complexity of choosing the correct marketing practices. It is recommended that only those marketing practices not contributing to customer equity should be outlawed by the Code. The indication is that the Code’s impact may reach further than just attempting to drive down the price of medicines; it may also impact the long term value of a pharmaceutical firm. Copyright / Dissertation (MBA)--University of Pretoria, 2010. / Gordon Institute of Business Science (GIBS) / unrestricted

In the world of business there are few industries that have challenged and overcome the world's economic troubles, that industry is pharmaceuticals. This industry has managed to stay one of the most lucrative businesses in the world because of its ability to adapt and the marketing skill to boost profits. This is achieved primarily through the pharmaceutical company's pharmaceutical representatives. These salespeople visit doctors and make them aware of their company's products and benefits. Since 1997, pharmaceutical companies have approached their business in a new way. The FDA approved Direct-to-Consumer advertising seen on T.V. and various other forms of media allowed these pharmaceutical companies to reach a whole new consumer. This reached their ultimate consumer, which had not been targeted before. As will be seen in this research, this advertising has had an affect on its target, whether that be the patient, the doctor, or the pharmaceutical salesperson. This is considered a pilot study because it is the beginning of research that will be done on the effects of Direct-to-Consumer advertising on the pharmaceutical salesperson's relationship and marketing approach with the doctor. This study was designed to research and determine the effects, if any, that this new form of advertising has had on how these pharmaceutical reps and their techniques have adjusted to this additional factor. The purpose is to determine if this advertising has had any degree of affect on the pharmaceutical rep and if their parent company has adapted.

The increase in use and distribution of pharmaceuticals on a global scale has caused pharmaceuticals to play an integral role in the notions of quality of health. This study is concerned with how Western medication is transacted and interpreted in explicit and implicit contrast to the other context. I observe the commercial trade of medicines, specifically the effects of regulation of pharmaceutical drug trade in a suburb of Johannesburg (Yeoville) a low income area where many migrant groups have found long and short term refuge. A Policing and Mobility Project (Hornberger & Cossa 2010) centred on tracing paths of medication and the level of policing thereof in Johannesburg revealed that clandestine sale of medication occurs in the suburb’s local market. This prompted a comparison between the formal and informal pharmaceutical trade spaces. Simon (a pharmacist) and Teresa (a former nurse turned market trader) sell pharmaceutical drugs in seemingly contrasting contexts. Despite their expertise in health care, Simon and Teresa were flung to opposite ends of the trade spectrum by regulation. In the weeks I spent with Teresa and Simon it became abundantly clear that the spaces which had been initially presented as the opposite of one another may have had a few layers of common ground. At first it seems as though only regulation has the ability to produce authority, trust and accountability. But later it becomes evident that such aspects can be reproduced through manipulation of everyday practices. Roger Cotterrell’s (1999) interpretation of Emile Durkheim’s view of the law as a ‘Social Fact’ (1999:9), demonstrates how the collective experience of regulation (an aspect of the law) affects the individual. But De Certeau (1984) claims that the same individual can tacitly undermine this collective experience (the dominant form) through everyday practices. The findings suggest that the assumed roles of regulated and unregulated pharmaceutical trading spaces are not as static as they appear. The study concluded that authority, trust and accountability can be reproduced outside of regulation. And secondly thus the formal and informal trade of pharmaceuticals in Yeoville have more in common than perceived since both Simon and Teresa, had authority in health, their customer’s trust and loyalty and were accountable within the trade.

Thesis (M.S.)--Ohio University, November, 1995. / Title from PDF t.p.

Thesis (Ph. D.)--Cornell University, 1991. / Vita. Includes bibliographical references (leaves 262-269).

No description available.

Thesis. 1979. Ph.D.--Massachusetts Institute of Technology. Dept. of Economics. / MICROFICHE COPY AVAILABLE IN ARCHIVES AND DEWEY. / Bibliography: leaves 176-179. / This thesis examines the effect that federal regulation of the product quality of new drugs (through safety and efficacy requirements) has had on the flow of new drugs onto the market place. The approach is to econometrically estimate these effects using disaggregated therapeutic class data from the 1970's. There are two primary estimations. First, the current effects of regulation on the production function relation between introductions and research expenditures are estimated. Second, the indirect effects of regulation on research effort are estimated in a research expenditures equation. These estimates are then combined to estimate the overall effect of regulation on introductions in the current era. In addition to the basic estimations described above, several important subsidiary issues are treated in the thesis. One is a discussion of the decline in new drug introductions of the 1962 era in terms of its individual therapeutic class components. This discussion gives strong support to the position that nonregulatory factors precipitated that decline in the rate of product introductions. Also, the project selection process of major pharmaceutical companies is examined in great detail. That discussion, and some econometric tests of hypotheses generated, clearly demonstrates that in order to predict how firms will respond to changes in environmental factors affecting profitability, one must first understand how firms collect, evaluate, and apply information concerning those factors. / Ph.D.